Search results for "Highlights"


 
Results 31 - 40 of about 54 for "Highlights".

8 weeks of ledipasvir/sofosbuvir may be effective for genotype 1 hepatitis C

The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
March 2017

Highlights

Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).
June 2019

Guideline released on treatment of Helicobacter pylori infection

Clarithromycin triple therapy should be used for first-line treatment of Helicobacter pylori infection only in patients with no history of macrolide exposure who live in areas where H. pylori resistance to clarithromycin is known to be low, among
January 2017

Induction, maintenance therapies for ulcerative colitis compared

Oral sulfasalazine, diazo-bonded 5-aminosalicylates (5-ASAs), mesalazine, controlled ileal-release budesonide, and budesonide multimatrix, alone or in combination with rectal 5-ASA therapy, were assessed for comparative efficacy and tolerability.
August 2018

GI safety profile varies among direct oral anticoagulants

Three propensity-matched cohorts of patients with nonvalvular atrial fibrillation who had incident exposure to dabigatran, rivaroxaban, or apixaban were compared.
January 2017

Lowering colorectal cancer screening age from 50 to 45 years appears cost-effective

Initiating screening at age 45 years would require an additional 10 million colonoscopies, which could potentially provide greater benefit if used instead to increase screening rates in older patients, authors of the modeling study said.
April 2019

Daily aspirin may reduce risk of hepatitis-related liver cancer

A Taiwanese nationwide cohort study of more than 10,000 patients with chronic hepatitis B showed a statistically significant 29% risk reduction for hepatocellular carcinoma in patients who received daily aspirin compared with matched controls.
March 2019

Tofacitinib more effective than placebo for ulcerative colitis, industry-funded study finds

The drug was evaluated in three multicenter, phase 3, randomized, double-blind, placebo-controlled trials involving patients with moderately to severely active disease.
May 2017

Endoscopic eradication therapy plus reflux control associated with decreased Barrett's recurrence rates

Standard reflux management protocol involved initial consultation that emphasized reflux control and proton-pump inhibitor (PPI) adherence, initiation or continuation of PPI therapy as described, medication reconciliation and assessment or
February 2017

Spotlight on esophageal adenocarcinoma

Although this study highlights a potential role of HPV status in the prognosis of esophageal adenocarcinoma, “the use of HPV as a predictive marker for treatment remains unproven,” an accompanying commentary
August 2018

Result Page: Prev   1   2   3   4   5   6   Next